Adrenal insufficiency in individuals with Duchenne muscular dystrophy treated with glucocorticoids: Insights from the past, current challenges, and future directions

Duchenne muscular dystrophy (DMD) is an X-linked recessive dystrophinopathy characterized by progressive loss of muscle strength, respiratory insufficiency, cardiac dysfunction, and premature death. Despite a rapidly evolving therapeutic landscape that now includes multiple disease modifying treatments including exon skipping medications, microdystrophin gene therapy, and givinostat, high dose glucocorticoids (GCs) initiated at a young age remain central to the standard of care for DMD. Individuals treated with GCs are at high risk of adrenal insufficiency, an iatrogenic and potentially life-threatening condition that can arise from adrenal suppression caused by prolonged exposure to supraphysiologic doses of GCs. The objective of this manuscript is to provide an up-to-date review of the best practices for the management of adrenal insufficiency in individuals with DMD treated with GCs. The approach described in this document also applies to individuals with related dystrophinopathies including Becker muscular dystrophy and female manifesting carriers treated with GCs, recognizing that GCs are not standard of care for these conditions and are prescribed on an individualized basis at some centers to severely affected individuals. Key themes discussed include best practices for individual and caregiver education about adrenal suppression, creation and implementation of stress steroid plans, safe transition between GC treatment regimens, and discontinuation of GC therapy.

Authors

Institutions

Publication Details

Journal
Journal of Neuromuscular Diseases
Published
2026-09-22
DOI
https://doi.org/10.1177/22143602261485046
Primary Topic
Muscle Physiology and Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Adrenal insufficiency in individuals with Duchenne muscular dystrophy treated with glucocorticoids: Insights from the past, current challenges, and future directions

Anne Marie Sbrocchi, Alberto Ferlin, Luisa De Sanctis, Kim Phung et al.
Journal of Neuromuscular Diseases
Muscle Physiology and Disorders
article

Adrenal insufficiency in individuals with Duchenne muscular dystrophy treated with glucocorticoids: Insights from the past, current challenges, and future directions

Anne Marie Sbrocchi, Alberto Ferlin, Luisa De Sanctis, Kim Phung, Janet L. Crane, Nat Nasomyont, Chiara Panicucci, Natascia Di Iorgi, Francesca Cumbo, Meilan M. Rutter, Shipra Bansal, Kathryn A. Selby, Eugenio Maria Mercuri, Nora E. Renthal, Stefan Nicolau, Sabrina Corbetta, Danilo Fintini, Gianluca Tornese, Luca Bello, Aravindhan Veerapandiyan, David R. Weber, Leanne Marie Ward, Robert W. Benjamin, Nadia Merchant, Hugh J. McMillan, Tommaso Aversa, Mélissa Fiscaletti, Maria-Elena Lautatzis, Julia Sorbara, Carol Lam, Mena Scavina, Susan Apkon, Kathi Kinnett, Laura McAdam, Alexandra Ahmet, Jaclyn Tamaroff, Paula R. Clemens, Sze Choong Wong, Cuixia Tian, Claire Wood, Rachel Schrader
article en

Abstract

Duchenne muscular dystrophy (DMD) is an X-linked recessive dystrophinopathy characterized by progressive loss of muscle strength, respiratory insufficiency, cardiac dysfunction, and premature death. Despite a rapidly evolving therapeutic landscape that now includes multiple disease modifying treatments including exon skipping medications, microdystrophin gene therapy, and givinostat, high dose glucocorticoids (GCs) initiated at a young age remain central to the standard of care for DMD. Individuals treated with GCs are at high risk of adrenal insufficiency, an iatrogenic and potentially life-threatening condition that can arise from adrenal suppression caused by prolonged exposure to supraphysiologic doses of GCs. The objective of this manuscript is to provide an up-to-date review of the best practices for the management of adrenal insufficiency in individuals with DMD treated with GCs. The approach described in this document also applies to individuals with related dystrophinopathies including Becker muscular dystrophy and female manifesting carriers treated with GCs, recognizing that GCs are not standard of care for these conditions and are prescribed on an individualized basis at some centers to severely affected individuals. Key themes discussed include best practices for individual and caregiver education about adrenal suppression, creation and implementation of stress steroid plans, safe transition between GC treatment regimens, and discontinuation of GC therapy.

Journal of Neuromuscular Diseases
Università Cattolica del Sacro Cuore (IT), University of Messina (IT), Cincinnati Children's Hospital Medical Center (US), Boston Children's Hospital (US), Nationwide Children's Hospital (US), Children's Hospital of Philadelphia (US), Harvard University (US), University of Padua (IT), University of British Columbia (CA), University of Trieste (IT), Johns Hopkins University (US), Thomas Jefferson University (US), University of Ottawa (CA), University of Pittsburgh (US), University of Toronto (CA), University of Milan (IT), Children's Hospital of Eastern Ontario (CA), Johns Hopkins Medicine (US), IRCCS Materno Infantile Burlo Garofolo (IT), Royal Hospital for Children (GB), Istituto Giannina Gaslini (IT), McGill University Health Centre (CA), Agostino Gemelli University Polyclinic (IT), Children's Hospital Colorado (US), Parent Project Muscular Dystrophy (US), Nemours Children's Health System (US), Royal Hospital for Sick Children (GB), Bambino Gesù Children's Hospital (IT), Duke Medical Center (US), IRCCS Istituto Auxologico Italiano (IT), Ospedale Regina Margherita (IT), Great North Children's Hospital (GB), Azienda Ospedale - Università Padova (IT), University of the Sacred Heart (JP), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Southwestern Medical Center (US), University of Manitoba (CA), The Ohio State University (US), University of Turin (IT), Université de Montréal (CA), University of Glasgow (GB), University of Pennsylvania (US), University of Arkansas for Medical Sciences (US), University of Genoa (IT), Newcastle University (GB), The University of Texas Southwestern Medical Center (US), Vanderbilt University Medical Center (US), University of Cincinnati Medical Center (US), University of Colorado Denver (US)
Good health and well-being
Openalex Percentile: Top 18%
Muscle Physiology and Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.